Women’s Health Diagnostics Market
New York, August 2023: According to a new research study by Global Insight Services (GIS), the global women’s health diagnostics market is expected to grow rapidly over the next 10 years to reach a value of more than the US $49.0 billion by 2032.
The women’s health diagnostic is a diagnostics method including screening, testing and monitoring of various women’s health disorders such as ovarian cancer, breast cancer, menopause, pregnancy and cervical cancer. For the diagnosis of women’s health-related diseases, various types of tests are available including Breast cancer testing, cervical cancer testing, prenatal genetic screening & carrier testing, pregnancy & ovulation testing, and ovarian cancer testing are all part of the diagnostic process. To avoid complications and improve quality of life, tests for screening and detection of various disorders are required. Health tests are essential for maintaining good health as well as preventing and treating serious diseases.
Request Sample Pages of this Research Report:
https://www.globalinsightservices.com/request-sample/GIS10385/
Women’s Health Diagnostics Market: Key Trends and Drivers
The growing awareness and prioritization of women’s health issues, coupled with advancements in medical technology. As societies increasingly recognize the importance of gender-specific healthcare, there is a heightened demand for accurate and specialized diagnostics tailored to women’s unique physiological and reproductive needs. Innovations in diagnostic techniques, such as non-invasive prenatal testing, advanced imaging modalities, and personalized genetic screenings, empower healthcare providers to detect and manage conditions like breast cancer, cervical abnormalities, and pregnancy-related complications with higher precision and early intervention. This evolving landscape not only enhances patient outcomes but also fosters collaborations between healthcare stakeholders, leading to the development of novel diagnostic solutions that cater to the distinct healthcare requirements of women, ultimately driving the growth of the Women’s Health Diagnostics Market.
Women’s Health Diagnostics Market: Restraints & Challenges
IThe growth of the Women’s Health Diagnostics Market may encounter limitations due to the significant costs associated with diagnostic procedures and the relatively low awareness among women about the importance of such procedures. The high financial burden of diagnostic tests could dissuade many women from seeking timely and necessary screenings, thereby impeding early detection and intervention for various health conditions specific to women. Additionally, the lack of awareness regarding the significance of diagnostic procedures may result in a delayed response to potential health issues, hindering the market’s expansion. Addressing these challenges through targeted awareness campaigns, improved accessibility to affordable diagnostics, and enhanced education about women’s health could play a pivotal role in overcoming these constraints and fostering the growth of the market..
Women’s Health Diagnostics Market Report Findings
https://www.globalinsightservices.com/reports/womens-health-diagnostics-market/
Diagnostic Device segment is likely to hold a dominant women’s health diagnostics market share and grow at a substantial CAGR during the forecast period.
Based on type, it is segmented into the diagnostic devices, diagnostic tests, accessories and consumables. In 2022, the diagnostics devices segment was the significant revenue generator and it is anticipated to grow at the fastest growth rate during the forecast period. This is driven by advancing technology and increasing awareness of gender-specific healthcare needs. These devices, ranging from ultrasound systems tailored for obstetric and gynecologic imaging to sophisticated mammography equipment, have gained prominence due to their pivotal role in early detection and accurate diagnosis of various women’s health conditions, including breast cancer, cervical abnormalities, and reproductive disorders. As medical innovations continue to enhance the precision and accessibility of these devices, coupled with rising efforts to prioritize women’s health, the diagnostics devices segment is poised to further expand, ensuring improved healthcare outcomes for women worldwide.
The breast cancer segment is anticipated to hold a majority of the women’s health diagnostics market size throughout the study period.
Based on application, it is segmented into breast cancer, infectious disease testing, osteoporosis testing, pregnancy and fertility testing, sexually transmitted disease testing, other applications. The breast cancer segment is likely to dominate the market during the forecast period. The largest share of the breast cancer is the most commonly occurring cancer in women and the second most common cancer worldwide. According to Globocan 2020, there were around 2,261,419 new breast cancer cases in 2020. The increasing cases resulted in increased sales of test kits for home usage, which is also expected to drive the market’s revenue growth over the forecast period. The rise in the adoption of point-of-care diagnostic testing and an increase in the number of diagnostic and imaging devices worldwide are expected to fuel the market growth.
The homecare settings segment is anticipated to hold a majority of the women’s health diagnostics market size throughout the study period.
Based on end-use, it is segmented into hospitals and clinics, diagnostic and imaging centers, homecare, others. The home care settings segment is expected to witness the highest growth during the forecast period. This expansion can be attributed to several factors, including increasing awareness among women about the importance of regular health check-ups, the convenience and comfort associated with receiving diagnostic services within the familiar setting of their homes, and the ongoing efforts to enhance patient-centric care. Additionally, the increasing advantages of using self-testing kits will continue to drive market growth. Patient self-testing enables patients to better manage their diseases by utilizing home/self-testing kits. Moreover, the COVID-19 pandemic further accelerated the adoption of home-based diagnostics, as many women sought safer alternatives to traditional healthcare facilities. Technological innovations such as portable ultrasound devices, at-home hormone level testing kits, and telemedicine platforms have empowered women to actively engage in monitoring their health, contributing to the growth of the homecare segment. As the healthcare landscape continues to evolve, the homecare segment is poised to play a pivotal role in the Women’s Health Diagnostics Market by providing personalized and accessible diagnostic solutions that cater to the unique needs of women, ultimately improving overall healthcare outcomes and quality of life.
The Asia-Pacific region is estimated to exhibit the highest growth rate during the women’s health diagnostics market forecast period.
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region is accounted for the majority of market share during the forecast period. The largest share of the region is primarily attributed to the favorable reimbursement policies for imaging procedures in the US, increased prevalence of cancer, and high investment by hospitals to purchase advanced diagnostics systems. Furthermore, increased research and development efforts have yielded innovative diagnostic tools tailored to women’s unique physiological needs, enabling more accurate and personalized assessments. The region’s robust healthcare infrastructure, coupled with substantial investments in healthcare research and development, has paved the way for the integration of cutting-edge technologies such as molecular diagnostics, advanced imaging modalities, and precision medicine approaches. As a result, the North American Women’s Health Diagnostics Market is witnessing substantial expansion, not only in terms of revenue but also in its ability to provide early detection and effective management of conditions such as breast cancer, cervical abnormalities, and hormonal imbalances, ultimately contributing to improved healthcare outcomes and enhanced quality of life for women across the continent.
Have a question for our analyst:
https://www.globalinsightservices.com/inquiry-before-buying/GIS10385/
Competitive Landscape
The global women’s health diagnostics market report includes players such as Abbott (U.S.), BD (U.S.), Cardinal Health, Inc. (U.S.), F.Hoffmann-La Roche Ltd. (Switzerland), General Electric Company (U.S.), Hologic, Inc. (U.S.), Koninklijke Philips N.V. (Netherland), Quest Diagnostics Incorporated (U.S.), Siemens Medical Solutions USA, Inc. (Germany), and bioMérieux SA. (U.S.)
In addition, major vendors are focused on developing smarter technologies and devices for cancer and other disease diagnostics. For instance, in January 2021, Roche launched its CE-IVD approved automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis for breast cancer. This launch was anticipated to expand its customer base and market share.
Recent Developments in the Women’s Health Diagnostics Market:
- In September 2021, Abbott acquired Walk Vascular LLC, a commercial-stage medical device firm with a minimally invasive mechanical aspiration thrombectomy system for the removal of peripheral blood clots.
- In April 2021, Carestream Health entered a partnership with Ziehm Imaging to provide Ziehm Vision RFD C-arm, a surgical imaging system included in the company’s mobile and fluoroscopic product offerings for ensuring exceptional image quality and reducing exposure significantly.
- In July 2019, Paragon Biosciences LLC launched Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.
- In June 2019, Genomic Health’s Oncotype DX Breast Recurrence Score test was approved by the German Federal Joint Committee for nationwide reimbursement.
Women’s Health Diagnostics Market Report Coverage
- The report offers a comprehensive quantitative as well as qualitative analysis of the current Women’s Health Diagnostics Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
- The report also covers qualitative as well as quantitative analysis of Women’s Health Diagnostics Market in terms of revenue ($Million).
- Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Women’s Health Diagnostics industry.
- A thorough analysis of market trends and restraints is provided.
- By region as well as country market analysis is also presented in this report.
- Analytical depiction of the Women’s Health Diagnostics Market along with the current trends and future estimations to depict imminent investment pockets. The overall Women’s Health Diagnostics industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
- Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Women’s Health Diagnostics Market are also analyzed.
Global Women’s Health Diagnostics Market Segments
By Type
- Diagnostic Devices
- Diagnostic Tests
- Accessories and Consumables
By Application
- Breast Cancer
- Infectious Disease Testing
- Osteoporosis Testing
- Pregnancy and Fertility Testing
- Sexually Transmitted Disease Testing
- Other Applications
By End-use
- Hospitals and Clinics
- Diagnostic and Imaging Centers
- Homecare
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Rest of World
- Latin America
- Middle East
- Africa
Key Players Profiled in the Report
- Abbott (U.S.)
- BD (U.S.)
- Cardinal Health, Inc. (U.S.)
- F.Hoffmann-La Roche Ltd. (Switzerland)
- General Electric Company (U.S.)
- Hologic, Inc. (U.S.)
- Koninklijke Philips N.V. (Netherland)
- Quest Diagnostics Incorporated (U.S.)
- Siemens Medical Solutions USA, Inc. (Germany)
- bioMérieux SA. (U.S.)